For the treatment of lung tumors, the CyberKnife VSI System can intelligently track respiratory motion in real-time and automatically adapt to changes in the patient's breathing pattern. For prostate cancer, the CyberKnife VSI System can address the unique challenges of random and excessive target motion by using intelligent and adaptive image guidance. These capabilities ultimately result in minimized dose to surrounding healthy tissue and critical structures, minimizing treatment complications and side effects.
"Our continued goal is to provide clinicians with an adaptive and superior treatment delivery system," said Eric Lindquist, SVP and chief marketing officer at Accuray. "CyberKnife VSI offers clinicians the flexibility to choose the treatment regimen they feel is best suited for their patients and further enhances the business case by expanding the number of patients it can treat."
Ad Statistics
Times Displayed: 113072
Times Visited: 6738 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
"There is a tremendous need for the capabilities built into the new CyberKnife VSI," said Dwight Heron, M.D., chairman of the Department of Radiation Oncology at UPMC Shadyside. "Depending on each individual patient's case, we will now be able to better tailor care so that the right amount of radiation is delivered to the right place in the right time frame for each patient, all with the same accuracy for which the CyberKnife is known."
For more information on the CyberKnife VSI System please visit: www.accuray.com/products/CyberKnife-VSI-System.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 70,000 patients worldwide and currently 180 Systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Back to HCB News
